IBRAHIM M S A W SHNAWA*
Since the down of human civilization that might begin with Chinese and Indian tradition in curing human as well as animal diseases they had had been using variety of remedies (Therapeutics) originated from both animal and plant resources. The human need for therapeutics led him almost always searching for new preparations . Now it is being an opportunity to gather hetero-genus preparations in a group-wise fashion as that of vaccine like, standard or standardized immune-biologics which have some features of vaccines in one proposed group designated as therapeutic vaccine allied biologics(TVAB) .To date it is being evident the proposal holding that at least there are five classes of(TVAB) available both at experimental level and to a lesser extent to the level of clinical use .The classes are as; cellular secretions(cytokines ,antibodies) ,receptor-anti-receptor(immune check point inhibitors) , subunit macromolecules (Beta Glucan) and commensal microbiome( probiotics) and Bacterio-therapeutics( cancer killing bacteria) . These proposed classes were evaluated by vaccine criteria as well as by a group specific special evaluation criteria ,collectively ,it is being a state of developing a novel evaluation system. They are helpful as therapeutics for ;microbial ,envenomation ,immune mediated and neoplastic diseases with variable degrees of success .
Wagner Quintilio*, Fábio Alessandro de Freitas, Cosue Miyaki and Isaias Raw
Adjuvanted trivalent influenza vaccines containing 3.75 µg of each antigen strain with alum and riboflavin or Bordetella pertussis MPLA were tested in mice. Immune response was evaluated by haemagglutination inhibition test, ELISA and antibody affinity test. The highest increase in antibody titers was obtained with the formulation containing MPLA. Significant increase in HAI titer was observed when mice received the formulation containing MPLA and alum, with a clear cross reaction between B lineages. Corroborating our previous results with monovalent vaccine, this study confirmed the adjuvant formulations containing MPLA or Riboflavin as promising adjuvants to be evaluated in clinical trials.
Biocore Publishing Group
All Published work is licensed under a Creative Commons Attribution 4.0 International License.